MAP2K7 and cancer: Small molecule inhibitors of Ras/MEK have recently progressed to clinical trials of cancer treatment and are proven to have low toxicity in vivo[62], [63] Therefore, it is a practical idea to use the combined therapy of IFN with Ras/MEK inhibitors in clinical settings to treat cancer patients.